Nephrotoxicity refers to the adverse effects of drugs and other chemical agents on renal structure and function, representing a significant cause of both acute kidney injury and chronic kidney disease. The kidneys are particularly vulnerable to toxic injury due to their high blood flow, their role in concentrating and eliminating waste products and xenobiotics, and the presence of specialized transport systems that can accumulate toxic substances within renal tubular cells. Drug-induced nephrotoxicity accounts for approximately 20 to 60 percent of cases of hospital-acquired acute kidney injury and contributes substantially to morbidity, mortality, and healthcare costs.
Mechanisms of injury vary across nephrotoxic agents but commonly involve direct tubular toxicity, altered intraglomerular hemodynamics, interstitial nephritis, and crystalline nephropathy. Direct tubular toxicity occurs when drugs accumulate within proximal tubular epithelial cells, disrupting mitochondrial function, inducing oxidative stress, and triggering apoptosis or necrosis. Hemodynamically mediated injury results from drugs that alter renal blood flow and glomerular perfusion, reducing the glomerular filtration rate without necessarily causing structural damage. Acute interstitial nephritis is an inflammatory reaction to a drug, often with an allergic component, while crystalline nephropathy results from the precipitation of drugs or their metabolites within tubular lumens.
Causative agents span multiple drug classes. Aminoglycoside antibiotics — including gentamicin, tobramycin, and amikacin — accumulate in proximal tubular cells and cause non-oliguric acute kidney injury in 10 to 25 percent of treated patients. Risk factors include prolonged therapy, high doses, preexisting renal impairment, and concurrent use of other nephrotoxins. Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce renal blood flow by inhibiting prostaglandin synthesis, leading to prerenal azotemia, and can also cause acute interstitial nephritis and papillary necrosis with chronic use. Contrast media, particularly older high-osmolality agents, cause contrast-induced nephropathy through renal vasoconstriction and direct tubular toxicity. Cisplatin accumulates in proximal tubular cells and produces dose-dependent nephrotoxicity that can be mitigated by aggressive hydration. Tenofovir disoproxil fumarate, an antiretroviral agent, causes proximal tubular dysfunction and Fanconi syndrome through mitochondrial toxicity.
Clinical presentation depends on the mechanism and site of injury. Acute tubular necrosis presents with a rapid rise in serum creatinine, often occurring three to five days after exposure to the nephrotoxic agent. Urinalysis may reveal granular casts and renal tubular epithelial cells. Acute interstitial nephritis typically develops one to two weeks after drug exposure and may be accompanied by fever, rash, eosinophilia, and sterile pyuria. Hemodynamically mediated injury produces a rapid but reversible decline in renal function. Chronic tubulointerstitial disease develops insidiously over months to years of exposure, manifesting as gradually rising creatinine, electrolyte abnormalities, and signs of tubular dysfunction such as glycosuria, phosphaturia, and acidosis.
Diagnosis and monitoring rely on serial serum creatinine measurements, urinalysis, and calculation of the estimated glomerular filtration rate. Novel biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) enable earlier detection of tubular injury before creatinine rises. Drug level monitoring is essential for aminoglycosides and other agents with narrow therapeutic indices. Imaging studies and renal biopsy may be indicated when the diagnosis is unclear or when recovery does not follow the expected course.
Prevention and management involve identifying high-risk patients, choosing less nephrotoxic alternatives when possible, adjusting doses for renal function, ensuring adequate hydration, and avoiding concurrent nephrotoxins. When nephrotoxicity develops, the offending agent should be discontinued or dose-reduced. Supportive measures include fluid and electrolyte management, avoidance of additional nephrotoxic insults, and, in severe cases, renal replacement therapy. Most drug-induced acute kidney injury is reversible if recognized promptly, though recovery may take weeks and some patients are left with permanent renal impairment.
